#USA #Heart Failure #Aliso Viejo #egnite #GDMT

Egnite 2026 Benchmark Report: Insights into Heart Failure Treatment

Overview

On October 21, 2026, egnite, Inc., a pioneering technology company in guideline-directed cardiovascular care, released its 2026 Benchmark Report. This vital document sheds light on the condition of heart failure treatment within 47 U.S. health systems, updating findings from the 2023 report based on a robust dataset comprising over 15.7 million patients.

Key Findings

One standout revelation within the report is the notable increase in the prescribing of all four classes of guideline-directed medical therapy (GDMT) for patients suffering from systolic heart failure, which has seen an increase from a mere 9% to 21%. Furthermore, the instance of patients receiving three or more GDMT classes rose significantly, from 31% to 46%. The rapid adoption of SGLT2 inhibitors has played a pivotal role in this progress.

The analysis covering more than 650,000 real-world patients diagnosed with systolic heart failure demonstrates a clear correlation between the number of GDMT classes prescribed and three-year survival rates. Patients who received all four classes registered a survival rate of 76%, contrasted with only 52% for those who did not receive any GDMT. This stark difference of 24 percentage points underscores the critical importance of comprehensive treatment.

Gaps in Treatment

Despite these positive trends, the report also reveals a concerning reality: a staggering 79% of systolic heart failure patients are still not receiving the full spectrum of GDMT. This statistic becomes all the more shocking when considering that contraindications for such therapy are exceptionally rare, reported at under 2% in the CHAMP-HF registry. Many patients remain untreated, potentially putting their health at risk and adding excess burden to acute care resources. The report indicates that the average health system witnesses about 1,050 systolic heart failure patients receiving no GDMT at all.

Notably, the data indicates that top-performing healthcare programs are prescribing three or more classes of GDMT at a rate 1.4 times greater than the lowest-performing systems, illustrating that the gap in treatment is surmountable with the right focus on patient care.

An additional concern highlighted in the report is that only 20% of systolic heart failure patients with multiple hospitalizations have ever consulted with a heart failure specialist. The lack of specialized care further emphasizes the need for systemic changes to improve patient management.

Proactive Approaches

Proactive heart care programs, such as the one at St. Luke's Heart and Vascular Institute in Chesterfield, MO, utilize the CardioCare® platform to enhance management of heart failure patients. The institute reported a significant 35 percentage point uptick in their four-class GDMT uptake between 2022 and 2026.

Lauren Lindner, a nurse practitioner at St. Luke's, stated, "In heart failure, data is your friend. CardioCare gives us benchmarking data and helps identify patients for outreach, allowing us to proactively manage this large population." This proactive approach could be instrumental in closing treatment gaps and enhancing patient outcomes moving forward.

Evolving Structural Heart Care

The report also addresses the significant under-treatment of severe tricuspid regurgitation (TR)— only 7% of symptomatic patients received appropriate treatment, marking a slight improvement from 6% in the previous report. Additionally, a concerning trend has emerged regarding untreated moderate aortic stenosis (AS); at median healthcare sites, the ratio of untreated moderate AS patients to untreated severe AS patients is strikingly high. This data indicates a critical need for ongoing patient monitoring and active management, particularly for those with moderate conditions who may be symptomatic but remain untreated.

Conclusion

As the healthcare landscape continues to evolve, the 2026 egnite Benchmark Report provides essential insights into the current state of heart failure treatment across the U.S. While progress is being made in prescribing GDMT, significant treatment gaps indicate that comprehensive frameworks and systematic changes are necessary to ensure every patient receives optimal care. With the right interventions and data-driven approaches, the possibilities for enhancing heart failure management can lead to improved patient outcomes nationwide.

About egnite

Founded in Aliso Viejo, California, egnite, Inc. is dedicated to improving cardiovascular care through cutting-edge technology solutions. The company’s CardioCare platform is operational at over 80 heart programs, utilizing extensive health data to prioritize patient care and facilitate transitions into evidence-based treatment pathways. For more information, please visit www.egnitehealth.com.